3196
R. S. G. R. Seixas et al.
LETTER
S.; Hostettmann, K. Phytochemistry 2004, 65, 963.
(b) Meepagala, K. A.; Schrader, K. K.; Wedge, D. E.; Duke,
S. O. Phytochemistry 2005, 66, 2689.
(13) Mai, H. D. T.; Gaslonde, T.; Michel, S.; Tillequin, F.; Koch,
M.; Bongui, J.-B.; Elomri, A.; Seguin, E.; Pfeiffer, B.;
Renard, P.; David-Cordonnier, M.-H.; Laine, W.; Bailly, C.;
Kraus-Berthier, L.; Léonce, S.; Hickman, J. A.; Pierré, A.
J. Med. Chem. 2003, 46, 3072.
(14) (a) Hughes, G. K.; Lahey, F. N.; Price, J. R.; Webb, L. J.
Nature (London) 1948, 162. (b) Tillequin, F.; Michel, S.;
Skaltsounis, A.-L. In Alkaloids: Chemical and Biological
Perspectives, Vol. 12; Pelletier, S. W., Ed.; Pergamon:
Oxford, 1998, 1–102.
(3) (a) Delmas, F.; Avellaneda, A.; Di Giogio, C.; Robin, M.;
De Clercq, E.; Timon-David, P.; Galy, J. J. Eur. J. Med.
Chem. 2004, 685. (b) Winter, R. W.; Kelly, J. X.;
Smilkstein, M. J.; Dodean, R.; Bagby, G. C.; Rathbun, R. K.;
Levin, J. I.; Hinrichs, D.; Riscoe, M. K. Exp. Parasitol.
2006, 114, 47. (c) Kelly, J. X.; Smilkstein, M. J.; Cooper,
R. A.; Lane, K. D.; Johnson, R. A.; Janowsky, A.; Dodean,
R. A.; Hinrichs, D. J.; Winter, R.; Riscoe, M. Antimicrob.
Agents Chemother. 2007, 51, 4133.
(15) Nishio, R.; Wessely, S.; Sugiura, M.; Kobayashi, S. J. Comb.
Chem. 2006, 8, 459.
(4) (a) Kawaii, S.; Tomono, Y.; Katase, E.; Ogawa, K.; Yano,
M.; Takemura, Y.; Juichi, M.; Ito, C.; Furukawa, H.
Leukemia Res. 1999, 23, 263. (b) Itoigawa, M.; Ito, C.; Wu,
T.-S.; Enjo, F.; Tokuda, H.; Nishino, H.; Furukawa, H.
Cancer Lett. 2003, 193, 133. (c) Harrison, R. J.; Reszka,
A. P.; Haider, S. M.; Romagnoli, B.; Morrell, J.; Read,
M. A.; Gowan, S. M.; Incles, C. M.; Kelland, L. R.; Neidle,
S. Bioorg. Med. Chem. Lett. 2004, 14, 5845.
(16) (a) Rudas, M.; Nyerges, M.; Toke, L.; Pete, B.;
Groundwater, P. W. Tetrahedron Lett. 1999, 40, 7003.
(b) Zhao, J.; Larock, R. C. J. Org. Chem. 2007, 72, 583.
(17) MacNeil, S. L.; Wilson, B. J.; Snieckus, V. Org. Lett. 2006,
8, 1133.
(18) 1-Methyl-4-quinolone-3-carbaldehyde(1) was prepared by a
Vilsmeier reaction of 2¢-aminoacetophenone, followed by
acidic hydrolysis of the resultant 4-chloroquinoline-3-
carbaldehyde to form 4-quinolone-3-carbaldehyde (8),
which was then N-methylated to avoid undesirable side
reactions of the amino group. The following procedure was
used: Coelho, A.; El-Maatougui, A.; Ravina, E.; Cavaleiro,
J. A. S.; Silva, A. M. S. Synlett 2006, 3324.
(5) (a) Tabarrini, O.; Cecchetti, V.; Fravolini, A.; Nocentini, G.;
Barzi, A.; Sabatini, S.; Miao, H.; Sissi, C. J. Med. Chem.
1999, 42, 2136. (b) Nakamura, S.; Kozuka, M.; Bastow,
K. F.; Tokuda, H.; Nishino, H.; Suzuki, M.; Tatsuzaki, J.;
Natschke, S. L. M.; Kuo, S.-C.; Lee, K.-H. Bioorg. Med.
Chem. 2005, 13, 4396. (c) Boumendjel, A.; Macalou, S.;
Ahmed-Belkacem, A.; Blanc, M.; Di Pietro, A. Bioorg. Med.
Chem. 2007, 15, 2892. (d) Gopinath, V. S.; Thimmaiah, P.;
Thimmaiah, K. N. Bioorg. Med. Chem. 2008, 16, 474.
(6) (a) Yamamoto, N.; Furukawa, H.; Ito, Y.; Yoshida, S.;
Maeno, K.; Nishiyama, Y. Antiviral Res. 1989, 12, 21.
(b) Fujiwara, M.; Okamoto, M.; Okamoto, M.; Watanabe,
M.; Machida, H.; Shigeta, S.; Konno, K.; Yokota, T.; Baba,
M. Antiviral Res. 1999, 43, 189. (c) Tabarrini, O.;
Manfroni, G.; Fravolini, A.; Cecchetti, V.; Sabatini, S.;
De Clercq, E.; Rozenski, J.; Canard, B.; Dutartre, H.;
Paeshuyse, J.; Neyts, J. J. Med. Chem. 2006, 49, 2621.
(7) (a) Goodell, J. R.; Madhok, A. A.; Hiasa, H.; Ferguson,
D. M. Bioorg. Med. Chem. 2006, 14, 5467. (b) Bernardino,
A. M. R.; Castro, H. C.; Frugulhetti, I. C. P. P.; Loureiro,
N. I. V.; Azevedo, A. R.; Pinheiro, L. C. S.; Souza, P. M. L.;
Giongo, V.; Passamani, F.; Magalhães, U. O.;
(19) Cava, M. P.; Deana, A. A. J. Am. Chem. Soc. 1959, 81, 4266.
(20) Optimized Experimental Procedure
A mixture of 1-methyl-4-quinolone-3-carbaldehyde (1,
121.7 mg, 0.65 mmol) and 1,3-dihydrobenzo[c]thiophene
2,2-dioxide (2a) in 1,2,4-trichlorobenzene (TCB, 6 mL) was
refluxed under a variety of reaction conditions (see Table 1).
After cooling to r.t., the reaction mixture was purified by
silica gel column chromatography; the TCB solvent was
removed using light PE as eluent, and then the cycloadducts
were eluted with a mixture of light PE–EtOAc (4:1). The
solvent was evaporated to dryness and the mixture of
diastereomers was separated by preparative thin-layer
chromatography using a mixture of light PE–EtOAc (9:1).
The 7-methylbenzo[b]-1,6,6a,12a-tetrahydroacridones 4
and 5 and the benzo[b]acridone(6) were obtained as yellow
compounds.
(21) Physical Data for cis-7-Methylbenzo[b]-1,6,6a,12a-
tetrahydroacridone (4)
Alburquerque, M. G.; Cabral, L. M.; Rodrigues, C. R.
Bioorg. Med. Chem. 2008, 16, 313.
1H NMR (300.1 MHz, CDCl3): d = 2.80–3.02 (m, 3 H,
1 × H-1, 2 × H-6), 3.11 (s, 3 H, NCH3), 3.31–3.36 (m, 1 H,
H-12a), 3.81 (dd, 1 H, J = 1.6, 17.3 Hz, H-1), 3.95 (dt, 1 H,
J = 5.5, 11.0 Hz, H-6a), 6.69 (d, 1 H, J = 8.6 Hz, H-8), 6.71
(ddd, 1 H, J = 0.9, 7.3, 7.6 Hz, H-10), 6.96 (d, 1 H, J = 7.4
Hz, H-5), 7.06 (dt, 1 H, J = 1.5, 7.4 Hz, H-4), 7.13 (dt, 1 H,
J = 1.3, 7.4 Hz, H-3), 7.20 (d, 1 H, J = 7.4 Hz, H-2), 7.41
(ddd, 1 H, J = 1.7, 7.3, 8.6 Hz, H-9), 7.86 (dd, 1 H, J = 1.7,
7.6 Hz, H-11). 13C NMR (75.47 MHz, CDCl3): d = 26.1 and
26.6 (C-1 and C-6), 37.6 (NCH3), 45.1 (C-12a), 60.4 (C-6a),
113.1 (C-8), 116.6 (C-10), 118.8 (C-11a), 125.8 (C-4), 126.4
(C-3), 127.9 (C-11), 129.1 and 129.2 (C-2 and C-5), 133.0
(C-5a), 133.8 (C-1a), 135.6 (C-9), 150.0 (C-7a), 194.1 (C-
12). ESI+-MS: m/z (%) = 264 (100) [M + H]+, 286 (93) [M +
Na]+, 302 (8) [M + K]+, 549 (47) [2 M + Na]+. HRMS (EI,
70 eV): m/z calcd for C18H17NO: 263.1310; found:
263.1309.
(8) Lowden, C. T.; Bastow, K. F. Antiviral Res. 2003, 59, 143.
(9) (a) Smith, J. A.; West, R. M. WO 099424, 2002; PCT/
GB2002/002509. (b) Taki, M.; Masahiko, S. WO 132335,
2006; PCT/JP2006/311561. (c) Blázquez, M. T.; Muñiz,
F. M.; Sáez, S.; Simón, L. M.; Alonso, A.; Raposo, C.;
Lithgow, A.; Alcázar, V.; Morán, J. R. Heterocycles 2006,
69, 73. (d) García-Garrido, S. E.; Caltagirone, C.; Light,
M. E.; Gale, P. A. Chem. Commun. 2007, 1450.
(10) (a) Costes, N.; Le Deit, H.; Michel, S.; Tillequin, F.; Koch,
M.; Pfeiffer, B.; Renard, P.; Léonce, S.; Guilbaud, N.;
Kraus-Berthier, L.; Pierré, A.; Atassi, G. J. Med. Chem.
2000, 43, 2395. (b) Tillequin, F. In Natural Products in the
New Millenium: Prospects and Industrial Applications;
Rauter, A. P.; Palma, F. B.; Justino, J.; Araújo, M. E.;
Santos, S. P., Eds.; Kluwer: Dordrecht, 2002, 311–328.
(c) Michel, S.; Gaslonde, T.; Tillequin, F. Eur. J. Med.
Chem. 2004, 649.
(22) Physical Data for trans-7-Methylbenzo[b]-1,6,6a,12a-
tetrahydroacridone (5)
(11) Nguyen, T. M.; Sittisombut, C.; Boutefnouchet, S.;
Lallemand, M.-C.; Michel, S.; Koch, M.; Tillequin, F.;
Mazinghien, R.; Lansiaux, A.; David-Cordonnier, M.-H.;
Pfeiffer, B.; Kraus-Berthier, L.; Léonce, S.; Pierré, A.
J. Med. Chem. 2006, 49, 3383.
1H NMR (300.1 MHz, CDCl3): d = 2.80–2.90 (m, 1 H,
H-12a), 2.91–3.01 (m, 1 H, H-1), 3.07 (s, 3 H, NCH3), 3.11–
3.16 (m, 1 H, H-6), 3.49–3.56 (m, 2 H, H-1, H-6), 3.57–3.63
(m, 1 H, H-6a), 6.81 (ddd, 1 H, J = 0.9, 7.3, 7.6 Hz, H-10),
6.90 (d, 1 H, J = 8.7 Hz, H-8), 7.18–7.25 (m, 4 H, H-2 to
(12) Koch, M. Bull. Acad. Nat. Med. 2007, 191, 83.
Synlett 2008, No. 20, 3193–3197 © Thieme Stuttgart · New York